Loading...
This study was undertaken to assess the effect on HIV incidence of rapid, targeted, high coverage rollout of preexposure prophylaxis (PrEP) for men who have sex with men (MSM) in Australia's most populous state, New South Wales. The partially manufacturer-funded study recruited primarily high-risk MSM within a network of 21 clinics who were provided free daily coformulated tenofovir disoproxil fumarate and emtricitabine. The primary endpoint was the within-cohort HIV incidence and change in overall new HIV diagnoses for the region comparing the 12-month periods before and after PrEP rollout.
Researchers recruited 3700 participants (median age, 36) from March 1 to October 31, 2016. During 4100 person-years, two participants became HIV infecte…